Le Lézard
Classified in: Health, Covid-19 virus
Subjects: CCA, ACC

Moberg Pharma: Interim report April - June 2020

STOCKHOLM, Aug. 11, 2020 /PRNewswire/ -- The Primary endpoint was met in the Phase 3 study


Comparative figures for the period refer to January 2019 - June 2019 (Note: 12 months vs. 6 months due to shortened fiscal year)'


Comparative figures for the fourth quarter refer to April 2019 - June 2019

* All comparative figures refer to continuing operations




In June, the results were presented from the second of two clinical studies in the Phase 3 program for MOB-015. As in the North American study, the European study met the primary endpoint and no serious adverse effects were identified. The superior mycological cure rate for MOB-015 has now been confirmed in two pivotal studies, strengthening our conviction that MOB-015 has the potential to become the future market leader in onychomycosis. We now look forward to finding the best path to approval in dialogue with our partners and regulatory agencies.

The European study was conducted at sites in Germany, the UK and Poland and included 452 patients with mild to moderate distal subungual onychomycosis (DSO) affecting 20-60 percent of the great toenail. Patients were randomized to daily treatment for 48 weeks, either with MOB-015 or 8 percent ciclopirox, the most widely used topical drug for onychomycosis.

Mycological cure was achieved in 84 percent of patients, which is unprecedented for a topical treatment and even higher than reported for oral treatments. The pattern is consistent with the results from the North American Phase 3 study, with a low complete cure rate despite the high mycological cure rate. The primary endpoint was met in the EU study as MOB-015 showed non-inferiority versus ciclopirox in achieving a complete cure at 52 weeks. The study results validate the previously presented conclusions: i) MOB-015 delivers a very high mycological cure rate, comparing favorably to oral antifungal drugs with the advantage of earlier onset of action; and ii) the vehicle enables efficient terbinafine delivery but also causes transient whitening/discoloration in nails, which contributes to the low complete cure rate reported.

With the primary endpoint achieved in both the North American study and the European study, the two studies can serve as a basis for product registration in Europe. For market approval in the U.S., the FDA normally requires two studies that show superiority (statistically superior to the comparator) for the primary endpoint. Consequently, an additional study is likely needed for U.S. registration.

This is an unusual situation that requires further dialogue with regulatory agencies and partners, since the outcomes of clinical studies normally are more uniform. In this case, the results for the two main parameters - complete cure and mycological cure - are fundamentally different. The very high mycological cure (ability to kill the fungus) is unprecedented but does not lead to a high complete cure rate, probably due to the observed transient whitening and discoloration of the nail, which complicates the assessment of clinical and complete cure. All experts engaged by Moberg Pharma agree that the high antifungal effect is extremely compelling, and that the product should over time be able to achieve a high rate of complete cure. We are therefore now discussing next steps for MOB-015 with our partners and regulatory agencies.

Anna Ljung, CEO of Moberg Pharma

CONFERENCE CALL - August 11, 2020 at 3:00 p.m. CET
CEO Anna Ljung will present the report at a telephone conference on August 11, 2020, at 3:00 p.m. CET.
Dial-in: SE: +46-8-505-583-50, US: +1-833-526-8382


This information is information that Moberg Pharma AB is obliged to make public persuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out below, at 8.00 a.m. CET on August 11th, 2020

Anna Ljung
Phone: +46-70-766-60-30
e-mail: anna.ljung@mobergpharma.se

Mark Beveridge,
VP Finance
Phone: +46-76-805-82-88
e-mail: mark.beveridge@mobergpharma.se

This information was brought to you by Cision http://news.cision.com


The following files are available for download:


Interim report April â?" June 2020

SOURCE Moberg Pharma

These press releases may also interest you

at 17:32
More than 12 years ago, Louise Bradley joined the Mental Health Commission of Canada (MHCC) as its chief operating officer. Two years later, she took over the helm as president and CEO ? and has been a steady hand at the wheel ever since. Today, it's...

at 17:30
Health Canada is advising Canadians that the following hand sanitizers are being recalled because they may pose health risks. For more information, including what Canadians should do, visit the online safety alert. Health Canada maintains this list...

at 17:12
TerrAscend Corp. ("TerrAscend" or the "Company") , a leading North American cannabis operator, today announced Jason Ackerman, Chief Executive Officer and Executive Chairman of TerrAscend, Keith Stauffer, Chief Financial Officer, and Jason Wild,...

at 17:10
The Cooperative of American Physicians, Inc. (CAP) announced today it has entered into a new relationship with Professional Security Insurance Company, a member of the well-known nationwide MagMutual Group and an A.M. Best "A" (Excellent) rated...

at 17:05
Radient Technologies Inc. ("Radient" or the "Company") , announces that the Company will be relying on the temporary 45 day extension to the filing deadline of its financial statements and management's discussion and analysis ("MD&A") for the quarter...

at 17:00
Pike Mountain Minerals Inc. ("Pike" or the "Company") and Carebook Technologies Inc. ("Carebook") announced today that on September 14, 2020, shareholders of Pike approved the previously announced business combination and reverse takeover transaction...

News published on 11 august 2020 at 02:16 and distributed by: